Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company that describes itself as a leading provider of autoimmune diagnostics and autoimmune testing solutions. Based in San Diego County, California, Exagen focuses on chronic and debilitating autoimmune conditions, particularly autoimmune rheumatic diseases. Its news flow reflects both its operational performance and its scientific and clinical activities in this specialized area.
Company news frequently covers financial results and operational updates, including quarterly earnings releases, preliminary annual results, and related guidance. These updates often discuss revenue trends, test volume for the AVISE CTD panel, average selling price metrics, and cash and cash equivalents, giving investors insight into Exagen’s commercial progress as an autoimmune diagnostics provider.
Exagen’s news also highlights developments in its testing portfolio and research programs. The company reports on enhancements to AVISE CTD, such as the commercial launch of seronegative rheumatoid arthritis markers for anti-PAD4, and on scientific milestones like the acceptance of multiple abstracts at the American College of Rheumatology’s annual meeting. These abstracts address topics including urinary biomarker panels for lupus nephritis, kidney-specific biomarker panels, T cell biomarkers, and multianalyte lupus risk scores.
Additional announcements include participation in healthcare and diagnostics investor conferences and leadership appointments, such as the addition of a Chief Scientific Officer and new board members with experience in life sciences and medical technology. Together, these news items give a view into Exagen’s financial performance, scientific focus, and corporate development. Investors and observers can use the XGN news page to follow how the company reports on its autoimmune testing business, research activities, and strategic initiatives over time.
Exagen Inc. (NASDAQ: XGN), a provider of autoimmune testing solutions, has appointed Chas McKhann to its Board of Directors, effective July 17, 2025. McKhann brings over 25 years of life sciences industry experience, having served as President and CEO of Silk Road Medical and Apollo Endosurgery, both successfully acquired by Boston Scientific.
McKhann's extensive background includes roles as Chief Commercial Officer at Torax Medical and Intersect ENT, along with significant experience in leading turnaround and transformational growth at medical technology companies. He holds degrees from Stanford University, including an M.B.A.
Exagen (NASDAQ: XGN), a leader in autoimmune testing, has scheduled its Q2 2025 financial results announcement for July 29, 2025, before market opening. The company will host a conference call at 8:30 AM ET featuring CEO John Aballi and CFO Jeff Black.
Investors can join via phone (201-389-0918 U.S. or +1-877-407-0890 international) or through the webcast link on Exagen's investor relations website. A replay will be available until August 12, 2025, accessible by phone using passcode 13753132 or through the company website.
Exagen Inc. (XGN) has successfully completed its public offering, raising approximately $20.2 million in gross proceeds. The offering included the sale of 3,350,000 shares of common stock, plus an additional 502,500 shares due to the full exercise of the underwriter's option, all priced at $5.25 per share. The transaction closed on May 9, 2025, with Canaccord Genuity acting as the sole bookrunner. The offering was conducted under Exagen's shelf registration statement previously filed with the SEC.
Exagen Inc. (XGN) has announced the pricing of its public offering of 3,350,000 shares of common stock at $5.25 per share. The offering is expected to generate gross proceeds of $17.6 million before deducting underwriting discounts and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 502,500 shares under the same terms.
The offering, scheduled to close on May 9, 2025, is being conducted through Canaccord Genuity as the sole bookrunner. The public offering is made pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on November 29, 2023.
Exagen Inc. (XGN) has secured a senior secured credit facility of up to $75 million with Perceptive Advisors The company received an initial $25 million tranche at closing to refinance existing debt with Innovatus Capital Partners and strengthen its balance sheet.
The facility includes additional tranches:
- $10 million available through March 2026 (revenue milestone-based)
- $10 million through December 2026 (revenue milestone-based)
- $30 million through March 2027 for business development initiatives
The loan terms include Term SOFR + 7% interest (SOFR floor 4.75%), 60-month interest-only payments, and warrants for 400,000 shares initially, with potential for 750,000 additional warrants tied to future tranches. The loan is secured by substantially all of Exagen's assets.
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, has scheduled its first quarter 2025 financial results announcement for May 5, 2025, before market opening. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) featuring President and CEO John Aballi and CFO Jeff Black.
Participants can join via phone at 201-389-0918 (U.S.) or +1-877-407-0890 (international), or through webcast available on the company's investor relations website. A replay will be accessible until May 19, 2025, through phone (201-612-7415 U.S., +1-877-660-6853 international, passcode 13753132) or webcast.
Exagen Inc. (XGN) reported strong financial results for Q4 and full-year 2024, achieving record total revenue of $55.6 million. The company demonstrated significant improvements in key metrics, including a 300 basis point increase in gross margin to 62.1% in Q4 and 59.5% for the full year.
The AVISE® CTD test reached a milestone of 1,000,000 patients tested, with its trailing twelve-month average selling price expanding to $411, a $75 increase per test. The company reduced its net loss by $1.8 million in Q4 and over $8 million for the full year compared to 2023.
Looking ahead, Exagen expects Q1 2025 revenue of at least $14.5 million and anticipates achieving positive adjusted EBITDA by Q4 2025. The company ended 2024 with $22.2 million in cash and restricted cash.